Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 2, 2004, Pages 169-178

  Visvikis, D ^a,c   Francis, D ^a   Mulligan, R ^a   Costa, D C ^a   Croasdale, I ^a   Luthra, S K ^b   Taylor, I ^a   Ell, P J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHU MORVAN   (France)

Author keywords

18FLT; Colorectal cancer; Quantitation

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; IN VIVO STUDY; MALE; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOACTIVITY; THORACIC AORTA;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGAN SPECIFICITY; RADIOISOTOPE DILUTION TECHNIQUE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 0842333886     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1339-2     Document Type: Article

References (43)

1. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 2:157-164.
2. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42:1S-93S.
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27.
4. Galandiuk S, Wieland HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174:27-32.
5. Thoeni RF. Colorectal cancer. Radiologic staging. Radiol Clin North Am 1997; 35:457-485.
6. 18F]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20:388-395.
7. Zeally IA, Skehan SJ, Rawlinson J, Coates G, Nahmias C, Somers S. Selection of patients for resection of hepatic metastases: improved detection of extra-hepatic disease with FDG PET. Radiographics 2001; 21:S55-S69.
8. Arulampalam T, Costa DC, Visvikis D, Boulos P, Taylor I, Ell PJ. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 2001; 28:1758-1765.
9. Swanson RS. Is an FDG-PET scan the new imaging standard for colon cancer? Ann Surg Oncol 2001; 8:752-753.
10. 18F-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
11. Bakheet SM, Powe J, Kandil A. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 2000; 25:100-103.
12. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25:259-264.
13. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61-77.
14. Shields AF, Mankoff DA, Link JM, Graham MW, Eary JF, Kozawa SM, Zheng M, Lewellen B, Lewellen TK, Grierson JR, Krohn KA. carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-1762.
15. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002; 43:492-499.
16. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189.
17. 11C labeled thymidine for tumor visualization using positron emission tomography. Appl Radiat Isot 1985; 35:705-708.
18. 11C]thymidine for quantification of cellular proliferation with PET. Appl Radiat Isot 1991; 42:103-104.
19. 18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27:143-156.
20. 18F]FLT). J Radioanal Nucl Chem 2000; 243:843-846.
21. 18F labeling of 3-Boc-1-(2-deoxy-3-O-nosyl-5-O-trityl-β-D-lyxofuranosyl)thymine and other thymine derivatives. J Nucl Med 2000; 41:255P.
22. Hengstschlager M, Knofler M, Mullner EW, Ogris E, Wintersberger E, Wawra E. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 1994; 269:13836-13942.
23. 3H]arabinothymidine, and cell analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002; 29: 281-287.
24. 18FLT. J Nucl Med 2000; 41:74P.
25. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-3334.
26. 18F]fluorothymidine uptake and retention in dogs. Mol Imag Biol 2002; 4:83-89.
27. 18FDG PET. Eur J Nucl Med 2001; 28:1326-1335.
28. Bettinardi V, Pagani E, Gilardi MC, Landoni C, Riddell C, Rizzo G, Castiglioni I, Belluzzo D, Lucignani G, Schubert S, Fazio F. An automatic classification technique for attenuation correction in positron emission tomography. Eur J Nucl Med 1999; 26:447-458.
29. DeGrado T, Turkington T, Williams J, Stearns C, Hoffman J. Performance characteristics of a whole body PET scanner. J Nucl Med 1994; 35:1398-1406.
30. 18F]fluorothymidine. J Lab Comp Radiopharm 2001; 44.
31. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
32. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998; 39:250-254.
33. Ohtake T, Kosaka N, Watanabe T, Yokohama I, Moritan T, Masuo M, Iizuka M, Kozeni K, Momose T, Oku S, Nishikawa J, Sasaki Y, Iio M. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991; 32:1432-1438.
34. Germano G, Chen BC, Huang SC, Gambhir SS, Hoffman EJ, Phelps ME. Use of the abdominal aorta for arterial input function determination in hepatic and renal PET studies. J Nucl Med 1992; 33:613-620.
35. 18F-FDG PET scans. J Nucl Med 2001; 42:1622-1629.
36. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7.
37. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple time uptake data: generalizations. J Cereb Blood Flow Metab 1985; 5:584-590.
38. 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000; 27:731-743.
39. Phelps ME, Mazziotta JC, Schelbert HR. Positron emission tomography and autoradiography (principles and applications for the brain and heart). New York: Raven, 1986.
40. Akaike H. A new look at the statistical identification. IEEE Trans Autom Contr 1978; 19:716-723.
41. Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 6:461-464.
42. 18FLT in patients. J Nucl Med 2000; 41:36P.
43. 18F-FDG in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30:988-994.